BioSpace News Archive

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 89,400 shares of Syros common stock to three newly hired employees in connection with their commencement of employment with Syros.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 295,000 shares of the company’s common stock to four new employees.

Natus Medical Incorporated, a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th.

Geron Corporation, a late-stage clinical biopharmaceutical company, announced the closing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of common stock, together with accompanying warrants to purchase 35,714,286 shares of common stock.

Surface Oncology, Inc. announced that Surface’s board of directors granted Theresa Boni, J.D., general counsel and senior vice president, legal, non-qualified stock options to purchase 120,000 shares of the company’s common stock with a per share exercise price of $2.87, the closing price of Surface’s common stock as reported by Nasdaq on April 1, 2022.

Athersys, Inc. announced that William Lehmann, President and Chief Operating Officer, will present a corporate overview at the virtual Locust Walk Stem Cell Conference on Monday, April 11, 2022 at 2:00 p.m. ET.

Oncternal Therapeutics, Inc. announced that it has granted an inducement award to one new employee, Rachel Monet Kenny, who joined the Company as Associate Director, CMC and Clinical Supply Chain.

Conformis, Inc., announced that Michael Fillion has joined the Company as its Chief Operating Officer.

NLS Pharmaceutics Ltd. announces that it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.

IVERIC bio, Inc. reported that on April 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 21 newly-hired, non-executive employees.